| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Akitsu Hotta | Q55135226 |
| P2093 | author name string | Peter Gee | |
| Kentaro Ishida | |||
| P2860 | cites work | Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. | Q52422958 |
| CRISPR-P: a web tool for synthetic single-guide RNA design of CRISPR-system in plants. | Q52422996 | ||
| Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells. | Q52423222 | ||
| E-CRISP: fast CRISPR target site identification | Q48332892 | ||
| Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. | Q52422824 | ||
| Ultrafast and memory-efficient alignment of short DNA sequences to the human genome | Q21183894 | ||
| BLAST+: architecture and applications | Q21284368 | ||
| Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs | Q21559464 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Heritable genome editing in C. elegans via a CRISPR-Cas9 system | Q24601099 | ||
| Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells | Q24634829 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9 | Q27011906 | ||
| Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation | Q27681624 | ||
| Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA | Q27681727 | ||
| Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease | Q27684893 | ||
| STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition | Q27701410 | ||
| Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease | Q28284509 | ||
| Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients | Q28303521 | ||
| Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification | Q29029259 | ||
| Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme | Q29308378 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| RNA-guided genetic silencing systems in bacteria and archaea | Q29614421 | ||
| Chimeric nucleases stimulate gene targeting in human cells | Q29615384 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| Improving CRISPR-Cas nuclease specificity using truncated guide RNAs | Q29616043 | ||
| High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy | Q30411331 | ||
| Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. | Q30458169 | ||
| CRISPR-Cas9 knockin mice for genome editing and cancer modeling | Q30607892 | ||
| CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells | Q30620756 | ||
| Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity | Q33566358 | ||
| Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases | Q33593394 | ||
| Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins | Q33657682 | ||
| Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells | Q33791002 | ||
| CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences | Q33791286 | ||
| Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. | Q33849553 | ||
| Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection | Q33854184 | ||
| CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing | Q33860682 | ||
| Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing | Q33875102 | ||
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. | Q33931841 | ||
| ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool | Q33957629 | ||
| Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. | Q33985245 | ||
| Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. | Q34040385 | ||
| In vivo genome editing using Staphylococcus aureus Cas9 | Q34043628 | ||
| CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation | Q34068759 | ||
| Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. | Q34088395 | ||
| Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells | Q34093413 | ||
| GT-Scan: identifying unique genomic targets | Q34136933 | ||
| Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac | Q34153816 | ||
| Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes | Q34175308 | ||
| A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. | Q34205743 | ||
| Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation | Q42083879 | ||
| Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. | Q42174678 | ||
| Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. | Q42359465 | ||
| CasOT: a genome-wide Cas9/gRNA off-target searching tool | Q44692208 | ||
| Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. | Q47822814 | ||
| Flexible guide-RNA design for CRISPR applications using Protospacer Workbench. | Q48165291 | ||
| Off-target mutations are rare in Cas9-modified mice. | Q48181926 | ||
| An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells | Q34424914 | ||
| Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA | Q34433586 | ||
| Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. | Q34436638 | ||
| CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. | Q34448898 | ||
| GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases | Q34454104 | ||
| Small molecule-triggered Cas9 protein with improved genome-editing specificity | Q34470608 | ||
| CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus | Q34478938 | ||
| Engineered CRISPR-Cas9 nucleases with altered PAM specificities | Q34481737 | ||
| Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells | Q34482784 | ||
| Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach | Q34484605 | ||
| Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. | Q34486935 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| Correction of a genetic disease in mouse via use of CRISPR-Cas9. | Q34658184 | ||
| COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites | Q34745306 | ||
| Targeting Hepatitis B Virus With CRISPR/Cas9. | Q34745348 | ||
| Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. | Q35060760 | ||
| sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites | Q35193366 | ||
| Determining the specificities of TALENs, Cas9, and other genome-editing enzymes | Q35422003 | ||
| Precision genome engineering with programmable DNA-nicking enzymes | Q36093894 | ||
| CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation | Q36591763 | ||
| Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos | Q36739960 | ||
| Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing | Q36834533 | ||
| Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. | Q37181372 | ||
| Heritable custom genomic modifications in Caenorhabditis elegans via a CRISPR-Cas9 system | Q37269749 | ||
| CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity | Q37271186 | ||
| Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. | Q37420333 | ||
| Genetic correction using engineered nucleases for gene therapy applications | Q38170509 | ||
| From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing | Q38592859 | ||
| Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells | Q38911544 | ||
| Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs | Q38977941 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| An unbiased genome-wide analysis of zinc-finger nuclease specificity | Q39493921 | ||
| DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases | Q40047890 | ||
| Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells | Q41265657 | ||
| Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. | Q41873090 | ||
| A guide RNA sequence design platform for the CRISPR/Cas9 system for model organism genomes. | Q42048707 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| organic chemistry | Q11351 | ||
| catalysis | Q82264 | ||
| mutagenesis | Q149299 | ||
| endonuclease | Q415601 | ||
| P304 | page(s) | 24751-24771 | |
| P577 | publication date | 2015-01-01 | |
| 2015-10-16 | |||
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases | |
| P478 | volume | 16 |
| Q64069727 | A novel method to investigate the effects of gene mutations at the cellular level using a dual expression lentiviral vector |
| Q47136073 | An efficient method for generation of bi-allelic null mutant mouse embryonic stem cells and its application for investigating epigenetic modifiers |
| Q92239450 | Anticipating Emerging Biotechnology Threats: A case study of CRISPR |
| Q62132626 | CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy |
| Q90483284 | CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects |
| Q93081159 | Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS |
| Q38791734 | Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects |
| Q39368114 | Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy |
| Q38810667 | Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases |
| Q26777421 | Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system |
| Q26752488 | Genome Engineering with TALE and CRISPR Systems in Neuroscience |
| Q92861337 | Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours |
| Q60912966 | Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech |
| Q38832507 | TALEN gene editing takes aim on HIV. |
Search more.